List of Excipients in Branded Drug PROPANTHELINE BROMIDE

« Back to Dashboard

Generic Drugs Containing PROPANTHELINE BROMIDE

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceuticals Corp	propantheline bromide	0054-4721	AMMONIA
West-Ward Pharmaceuticals Corp	propantheline bromide	0054-4721	BUTYL ALCOHOL
West-Ward Pharmaceuticals Corp	propantheline bromide	0054-4721	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in PROPANTHELINE BROMIDE?

# Of NDCs	Excipient
1	AMMONIA
1	BUTYL ALCOHOL
1	FERROSOFERRIC OXIDE

Propantheline Bromide Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Propantheline bromide is an old quaternary ammonium antimuscarinic with limited contemporary commercial presence and no meaningful composition-of-matter exclusivity. The strongest opportunity is a low-cost, stable immediate-release oral tablet supplied through generic, specialty, hospital, or international channels. Excipient differentiation can support regulatory approval, manufacturing reliability, swallowability, taste masking, and selective lifecycle extensions, but the molecule’s therapeutic tolerability limits premium positioning.

What is the commercial status of propantheline bromide?

Propantheline bromide is an orally administered anticholinergic historically used for gastrointestinal spasm, peptic-ulcer adjunct treatment, and reduction of excessive gastrointestinal secretions. It is a quaternary ammonium compound that has limited central nervous system penetration relative to tertiary amine antimuscarinics, although peripheral anticholinergic adverse effects remain clinically important.

Attribute	Propantheline bromide
Active ingredient	Propantheline bromide
Pharmacologic class	Peripheral antimuscarinic, quaternary ammonium compound
Historical oral strength	15 mg tablets
Molecular formula	C23H30BrNO3
Molecular weight	Approximately 448.4 g/mol
Primary dosage form	Immediate-release oral tablet
Historical U.S. brand	Pro-Banthine
Current U.S. opportunity	Generic or reformulated product, subject to current FDA pathway and reference-product status
Composition-of-matter position	Expired
Main commercial constraints	Limited prescribing, anticholinergic tolerability, competition from newer therapies

The product has historical FDA labeling, but its current U.S. marketing status is weaker than that of actively marketed contemporary antimuscarinics. A sponsor must verify the current reference-listed drug and regulatory pathway before selecting an abbreviated application strategy. FDA’s Orange Book distinguishes active approved products from discontinued products and identifies patents and exclusivity only where applicable [1].

What excipient strategy is best for propantheline bromide tablets?

The best initial formulation is a conventional immediate-release tablet using a low-complexity excipient system. A standard target would be a 15 mg tablet with rapid disintegration, adequate mechanical strength, low friability, and protection from moisture.

Recommended immediate-release formulation platform

Formulation function	Candidate excipients	Development rationale
Diluent	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate	Controls tablet weight and compression
Binder	Povidone, copovidone, pregelatinized starch	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid disintegration
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection and tooling friction
Film coat	Hypromellose, polyethylene glycol, titanium dioxide or approved colorant	Improves appearance and handling
Moisture control	High-barrier blister or HDPE bottle with desiccant	Reduces humidity exposure

A direct-compression formula is commercially attractive because it minimizes processing steps and lowers manufacturing cost. Microcrystalline cellulose with mannitol or lactose can provide acceptable compactability and mouthfeel. If flow or content-uniformity performance is poor, dry granulation is more defensible than wet granulation because it reduces water exposure.

Propantheline bromide is a relatively low-dose active ingredient in a comparatively high-molecular-weight salt form. Content uniformity, powder segregation, and electrostatic behavior should receive early attention. A geometric dilution step or ordered mixing process may be required before compression.

Why moisture and pH screening matter

Propantheline bromide should be evaluated across a controlled excipient compatibility matrix rather than assumed to be stable with all conventional tablet ingredients. The development program should compare:

• Lactose-containing versus lactose-free formulas.
• Anhydrous and hydrated excipient grades.
• Neutral or mildly acidic microenvironments.
• Magnesium stearate and sodium stearyl fumarate lubrication systems.
• High- and low-moisture packaging.
• Ambient, accelerated, and high-humidity storage.

A conservative strategy is to avoid strongly alkaline excipients during early screening and to monitor assay, related substances, dissolution, water content, and tablet appearance. The bromide salt is ionic, so the effect of excipient moisture, ionic strength, and local microenvironment should be measured experimentally. A neutral filler system based on microcrystalline cellulose and mannitol is a reasonable first platform where lactose or alkaline mineral excipients create uncertainty.

What formulations are protected by propantheline bromide patents?

No commercially meaningful active U.S. composition-of-matter patent position remains for propantheline bromide. The molecule and its historical oral use date to the mid-20th century. Any original compound, basic tablet, or conventional oral-use patent rights have long expired.

IP category	Current commercial relevance
Original compound patent	Expired
Conventional 15 mg tablet	No meaningful remaining exclusivity
Standard excipient combination	Generally unprotectable unless technically novel and non-obvious
Modified-release formulation	Potentially patentable if supported by unexpected performance
Taste-masked dosage form	Potentially patentable, but crowded
Orally disintegrating tablet	Potentially patentable only with specific technical advantages
New indication	Potential method-of-use opportunity, subject to clinical evidence
Manufacturing process	Potentially patentable if the process solves a reproducible technical problem

A new patent would need to claim a genuine formulation or manufacturing distinction. Merely substituting mannitol for lactose, or croscarmellose sodium for crospovidone, would usually provide weak patent protection without unexpected stability, dissolution, bioavailability, or usability data.

How strong is the patent estate for propantheline bromide?

The patent estate is weak from an exclusivity perspective and potentially useful only for a differentiated follow-on product. The strongest possible claims would concern:

1. A moisture-protective formulation with demonstrated long-term stability.
2. A low-dose tablet with improved content uniformity.
3. A palatable orally disintegrating tablet for patients unable to swallow.
4. A modified-release formulation that reduces peak-related adverse effects.
5. A combination product supported by a new clinical use.
6. A manufacturing process that improves yield, impurity control, or scale-up.

The commercial value of such claims would depend on clinical adoption and reimbursement, not merely on patent issuance. A narrow formulation patent would not block conventional generic tablets unless the marketed product depended on the claimed technology.

What FDA regulatory pathway applies to a new propantheline bromide product?

The likely pathway depends on whether FDA identifies an active reference-listed drug and whether the proposed product matches its dosage form, strength, route, labeling, and performance characteristics.

Potential U.S. pathways

Product concept	Potential pathway
Conventional tablet matching an active RLD	ANDA under section 505(j)
Reformulated product with clinical or pharmacokinetic differences	505(b)(2) application
New indication or new clinical profile	505(b)(2) or full NDA, depending on reliance and evidence
Product with no suitable active RLD	505(b)(2) or NDA strategy
Hospital compounded product	Not a conventional commercial approval pathway

An ANDA sponsor would typically need to address pharmaceutical equivalence, assay, impurities, dissolution, stability, labeling, and bioequivalence. A 505(b)(2) application may offer greater formulation flexibility but can require additional clinical or pharmacokinetic evidence and may face listed-patent certifications where applicable [1,2].

FDA’s product-specific guidance, dissolution expectations, and current Orange Book entries should control the final strategy. The absence of a practical patent barrier does not eliminate regulatory risk if the historical reference product is discontinued or if FDA requires a different evidentiary bridge.

What is the Orange Book status of propantheline bromide?

Propantheline bromide does not have a commercially important modern Orange Book patent or exclusivity position comparable with newer branded drugs. The key issue is not patent expiry but reference-product and market-status verification.

For a U.S. launch, the sponsor should distinguish among:

• A previously approved but discontinued product.
• A product that remains eligible as a reference for an abbreviated application.
• A drug requiring a 505(b)(2) approach because no suitable active reference is available.
• A product requiring a new NDA because the proposed clinical profile is materially different.

Paragraph IV litigation risk appears low for the historical molecule itself. If a sponsor files a new formulation patent and lists it in the Orange Book, later applicants could challenge the listed patent through a Paragraph IV certification. That risk would arise from the sponsor’s new patent strategy, not from the old propantheline bromide tablet.

When does propantheline bromide lose exclusivity?

The relevant exclusivity has already expired for the historical compound and conventional oral formulation. There is no expected new-compound exclusivity period for a standard generic tablet.

A new sponsor could obtain limited regulatory or patent protection only by developing a new product profile, such as:

New product feature	Potential protection
New formulation	Patent, if novel and non-obvious
New indication	Three-year clinical-investigation exclusivity may be possible for certain 505(b)(2) approvals
New chemical entity	Not applicable to the established molecule
Orphan indication	Possible orphan exclusivity only if statutory criteria are satisfied
Pediatric studies	Potential pediatric exclusivity if requested and completed under FDA requirements

These protections would attach to the new development program, not to the underlying historical tablet.

What generic entry risks exist for propantheline bromide?

Generic entry risk is high for a conventional immediate-release tablet because:

• The active ingredient is old.
• The product is chemically defined.
• Conventional excipients are inexpensive.
• Manufacturing does not require complex delivery technology.
• No meaningful compound patent appears to block entry.
• Therapeutic substitution may limit the value of brand differentiation.

The principal obstacles are commercial rather than intellectual-property based. A sponsor may face low prescription volume, limited formulary demand, weak physician familiarity, and competition from newer agents such as oxybutynin, glycopyrrolate, hyoscyamine, and other therapies selected by indication.

Which excipient-led products offer the strongest commercial opportunity?

1. Low-cost conventional tablet

This is the lowest-risk product. A 15 mg immediate-release tablet in a moisture-protective package could serve generic, institutional, and international markets. The product should prioritize reliable dissolution and supply continuity rather than cosmetic differentiation.

2. Lactose-free or gluten-free tablet

A lactose-free formulation could address a practical procurement requirement, although the commercial premium would probably be modest. Mannitol, microcrystalline cellulose, or dibasic calcium phosphate can replace lactose depending on compression and dissolution results.

3. Orally disintegrating tablet

An orally disintegrating tablet could target patients with dysphagia or those needing discreet administration. Mannitol, crospovidone, a taste-masking polymer, and a low-moisture blister are plausible starting points.

The principal technical risks are bitterness, friability, moisture sensitivity, and rapid drug release. Propantheline’s potent peripheral anticholinergic effects also make accidental overexposure undesirable. Taste masking must not delay dissolution or create dose dumping.

4. Modified-release tablet

A modified-release product could reduce dosing frequency or peak-related adverse effects. Hydrophilic matrix systems using hypromellose, polyethylene oxide, or polymer-coated multiparticulates are possible platforms.

This opportunity is less attractive than an immediate-release generic because it requires stronger pharmacokinetic justification, more complex dissolution control, and potentially a 505(b)(2) program. A modified-release product would also need to demonstrate that prolonged exposure does not worsen dry mouth, constipation, urinary retention, blurred vision, tachycardia, or heat-intolerance risk.

5. Specialty product for excessive sweating

Propantheline has been used in some markets for hyperhidrosis. A formulation positioned for that use could support a specialty strategy, but a new indication would require evidence, compliant labeling, and a defined patient population. An extended-release product could be commercially relevant if it reduces dosing burden without increasing adverse effects.

How does propantheline bromide compare with competing anticholinergic drugs?

Product	Commercial position	Formulation implication
Propantheline bromide	Older, low-volume, generic-oriented	Cost and availability are central
Oxybutynin	Broad anticholinergic use, multiple dosage forms	Competes strongly on familiarity and extended release
Glycopyrrolate	Peripheral anticholinergic use, several formulations	Competes where low CNS penetration is valued
Hyoscyamine	Gastrointestinal antispasmodic market	Competes on indication and prescribing habits
Scopolamine	Transdermal and other delivery systems	Different indication and delivery profile
Atropine	Broader systemic use	Less direct formulation comparison

Propantheline’s potential advantage is its established peripheral antimuscarinic pharmacology. Its disadvantages are limited current market visibility, anticholinergic tolerability, and the absence of a modern differentiated delivery system.

What manufacturing and IP barriers affect propantheline bromide?

The active pharmaceutical ingredient is not expected to create a major manufacturing barrier compared with complex small molecules or biologics. The main technical risks are:

• Assay and content uniformity at low tablet strength.
• Moisture-driven degradation or physical instability.
• Powder flow and segregation.
• Residual solvent and impurity control in the API.
• Reproducible dissolution across scale.
• Packaging performance in humid climates.
• Stability of orally disintegrating or modified-release systems.

A sponsor can create manufacturing know-how around controlled granulation, low-moisture processing, continuous blending, high-barrier packaging, and impurity specifications. That know-how may support freedom to operate and product quality but does not automatically create enforceable market exclusivity.

What licensing deals and litigation affect propantheline bromide?

No major current licensing transaction or active branded-generic patent dispute is associated with the historical propantheline bromide tablet market in the public record. The principal litigation exposure would arise if a new sponsor:

• Listed a formulation patent in the Orange Book.
• Claimed a new method of use.
• Developed a 505(b)(2) product relying on protected reference labeling.
• Used a proprietary modified-release or taste-masking technology.

For a conventional generic, Paragraph IV risk is likely limited because there is no apparent active patent estate of commercial significance. For a newly patented product, later applicants could challenge formulation or method-of-use claims under the Hatch-Waxman framework [2].

What is the revenue opportunity for a propantheline bromide product?

The opportunity is best characterized as niche and supply-driven rather than blockbuster-oriented. Revenue depends on:

1. Whether an active U.S. reference pathway is available.
2. The number of competing generic suppliers.
3. Hospital and wholesaler demand.
4. International availability and local registration requirements.
5. Differentiation through dosage form or indication.
6. Ability to maintain uninterrupted API supply.

A conventional generic tablet can be attractive where competition is limited and manufacturing is efficient. A premium reformulation requires stronger evidence of patient benefit because physicians and payers may substitute inexpensive anticholinergic alternatives.

What geographic markets are most attractive?

The most practical geographic strategy is a staged launch:

Market	Commercial assessment
United States	Regulatory pathway and current reference status require close review
United Kingdom and Europe	National authorization and local reference-product requirements apply
Australia and New Zealand	Established regulatory systems with niche generic opportunities
Latin America	Potential demand, but registration and procurement vary materially
Middle East and Asia	Opportunity may depend on local brand history and hospital channels
Low- and middle-income markets	Price-sensitive, with packaging and supply reliability important

A high-barrier blister may be unnecessary in dry markets but valuable in tropical or high-humidity regions. A lactose-free, heat-stable tablet could have more practical value internationally than a complex premium dosage form.

Key Takeaways

• Propantheline bromide has no meaningful remaining composition-of-matter exclusivity.
• The strongest initial product is a 15 mg immediate-release tablet with a simple, moisture-controlled excipient system.
• Microcrystalline cellulose, mannitol or lactose, crospovidone or croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate are reasonable development candidates.
• Moisture, impurity formation, content uniformity, and dissolution should drive excipient selection.
• A conventional generic faces high entry risk and limited pricing power.
• Orally disintegrating and modified-release products offer differentiation but require greater regulatory and clinical investment.
• U.S. strategy depends on confirming the current Orange Book reference-product status.
• Patent value is more likely to arise from a technically supported formulation or process than from the historical drug itself.
• Commercial potential is niche, with the best opportunities in supply-constrained generic, hospital, international, and specialty markets.

FAQs About Propantheline Bromide Formulation and Commercialization

Can propantheline bromide be formulated as an orally disintegrating tablet?

Yes. Mannitol, crospovidone, a taste-masking system, and a high-barrier blister are plausible starting components. The main development risks are bitterness, friability, moisture uptake, and rapid but complete dissolution.

Is lactose suitable for propantheline bromide tablets?

Lactose may be suitable, but it should be evaluated in compatibility and stability studies against lactose-free alternatives. The preferred filler depends on impurity profile, water activity, compression behavior, and dissolution performance.

Does propantheline bromide have biosimilar competition?

No. Propantheline bromide is a small-molecule drug, so it is subject to generic-drug pathways rather than biosimilar regulation.

Could a new propantheline bromide indication receive market exclusivity?

A new indication supported by qualifying clinical investigations may receive limited regulatory exclusivity under applicable FDA rules. The exclusivity would cover the approved use, not the old molecule broadly.

Is a sustained-release propantheline bromide product commercially defensible?

It could be defensible if it demonstrates fewer daily doses, acceptable exposure, improved adherence, or reduced peak-related adverse effects. The evidence burden and development cost would be materially higher than for a conventional immediate-release generic.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2015). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs

3. U.S. National Library of Medicine. (n.d.). Propantheline bromide. PubChem. https://pubchem.ncbi.nlm.nih.gov/

4. U.S. National Library of Medicine. (n.d.). Pro-Banthine, propantheline bromide tablet labeling. DailyMed. https://dailymed.nlm.nih.gov/

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

6. European Medicines Agency. (n.d.). Generic and hybrid medicines. https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/generic-hybrid-medicines